Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16662380 | 0.85 | ADORA2A (0.35) | RECQLADORA2AADORA2BADORA1SMN1; SMN2 | |
| SCHEMBL1662616 | 0.82 | PDE2A (0.33) | RECQL | |
| SCHEMBL17076748 | 0.82 | — | — | |
| SCHEMBL15652340 | 0.82 | ADA (0.30) | — | |
| SCHEMBL15650617 | 0.82 | — | — | |
| SCHEMBL12427864 | 0.82 | RPS6KB1 (0.35) | ALDH1A1RPS6KB1GSK3BACHEADORA3 | |
| SCHEMBL19121717 | 0.79 | ACHE (0.35) | ACHESMN1; SMN2 | |
| SCHEMBL20555402 | 0.78 | — | — | |
| SCHEMBL20555403 | 0.78 | — | — | |
| SCHEMBL267216 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358879-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-15 | — | — | US | disclosed |
| EP-4046688-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-12060357-B2 | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | MERCK SHARP & DOHME LLC (US) | 2024-08-13 | — | — | US | disclosed |
| WO-2023217851-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF-κB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
| US-20230322683-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | US | disclosed |
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| EP-4046688-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2022-08-24 | — | — | EP | disclosed |
| US-20220220117-A1 | 9-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2022-07-14 | — | — | US | disclosed |
| WO-2021075476-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2021-04-22 | — | — | WO | disclosed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220117-A1 | 9-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | ADORA2A, ADORA2B, ADORA3 | ALDH1A1 815/4885RPS6KB1 694/4885GSK3B 1223/4885 |
| US-20230322683-A1 | HETEROCYCLIC COMPOUND | PARK7, SMN1; SMN2, SNCA | ALDH1A1 1856/4885RPS6KB1 2296/4885GSK3B 498/4885 |
| US-12060357-B2 | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | ADORA2A, ADORA2B, ADORA3 | ALDH1A1 815/4885RPS6KB1 694/4885GSK3B 1223/4885 |
| US-12358879-B2 | Heterocyclic compound | PARK7, SMN1; SMN2, SNCA | ALDH1A1 1856/4885RPS6KB1 2296/4885GSK3B 498/4885 |
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | ABL2, ABL1, ALK | ALDH1A1 651/4885RPS6KB1 3771/4885GSK3B 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.